Randomization methods — MCQs

10 questions

A 38-year-old project manager is told by her boss that her team will need to work on an additional project in the coming week for a very important client. This frustrates the woman, who already feels that she works too many hours. Instead of discussing her feelings directly with her boss, the woman leaves a voice message for her boss the next day and deceitfully says she cannot come to work for the next week because of a family emergency. Which of the following psychological defense mechanisms is this individual demonstrating?

A researcher is conducting a study to compare fracture risk in male patients above the age of 65 who received annual DEXA screening to peers who did not receive screening. He conducts a randomized controlled trial in 900 patients, with half of participants assigned to each experimental group. The researcher ultimately finds similar rates of fractures in the two groups. He then notices that he had forgotten to include 400 patients in his analysis. Including the additional participants in his analysis would most likely affect the study's results in which of the following ways?

A pharmaceutical company conducts a randomized clinical trial to demonstrate that their new anticoagulant drug, Aclotsaban, prevents more thrombotic events following total knee arthroplasty than the current standard of care. A significant number of patients are lost to follow-up, and many fail to complete treatment according to the study arm to which they were assigned. Despite these protocol deviations, the results for the patients who completed the course of Aclotsaban are encouraging. Which of the following analytical approaches is most appropriate for the primary analysis to establish the efficacy of Aclotsaban?

In the study, all participants who were enrolled and randomly assigned to treatment with pulmharkimab were analyzed in the pulmharkimab group regardless of medication nonadherence or refusal of allocated treatment. A medical student reading the abstract is confused about why some participants assigned to pulmharkimab who did not adhere to the regimen were still analyzed as part of the pulmharkimab group. Which of the following best reflects the purpose of such an analysis strategy?

An experimental drug, ES 62, is being studied. It prohibits the growth of vancomycin-resistant Staphylococcus aureus. It is highly lipid-soluble. The experimental design is dependent on a certain plasma concentration of the drug. The target plasma concentration is 100 mmol/dL. Which of the following factors is most important for calculating the appropriate loading dose?

A research group wants to assess the safety and toxicity profile of a new drug. A clinical trial is conducted with 20 volunteers to estimate the maximum tolerated dose and monitor the apparent toxicity of the drug. The study design is best described as which of the following phases of a clinical trial?

An epidemiologist is evaluating the efficacy of Noxbinle in preventing HCC deaths at the population level. A clinical trial shows that over 5 years, the mortality rate from HCC was 25% in the control group and 15% in patients treated with Noxbinle 100 mg daily. Based on this data, how many patients need to be treated with Noxbinle 100 mg to prevent, on average, one death from HCC?

You are currently employed as a clinical researcher working on clinical trials of a new drug to be used for the treatment of Parkinson's disease. Currently, you have already determined the safe clinical dose of the drug in a healthy patient. You are in the phase of drug development where the drug is studied in patients with the target disease to determine its efficacy. Which of the following phases is this new drug currently in?

A pharmaceutical company conducts a randomized clinical trial in an attempt to show that their new anticoagulant drug prevents more thrombotic events following total knee arthroplasty than the current standard of care. However, a significant number of patients are lost to follow-up or fail to complete treatment according to the study arm to which they were assigned. Several patients in the novel drug arm are also switched at a later time to a novel anticoagulant or warfarin per their primary care physician. All patients enrolled in the study are subsequently analyzed based on the initial group they were assigned to and there is a significant improvement in outcome of the new drug. What analysis most appropriately describes this trial?

Q10

A study seeks to investigate the therapeutic efficacy of treating asymptomatic subclinical hypothyroidism in preventing symptoms of hypothyroidism. The investigators found 300 asymptomatic patients with subclinical hypothyroidism, defined as serum thyroid-stimulating hormone (TSH) of 5 to 10 μU/mL with normal serum thyroxine (T4) levels. The patients were randomized to either thyroxine 75 μg daily or placebo. Both investigators and study subjects were blinded. Baseline patient characteristics were distributed similarly in the treatment and control group (p > 0.05). Participants' serum T4 and TSH levels and subjective quality of life were evaluated at a 3-week follow-up. No difference was found between the treatment and placebo groups. Which of the following is the most likely explanation for the results of this study?

Randomization methods US Medical PG Practice Questions and MCQs

Question 1: A 38-year-old project manager is told by her boss that her team will need to work on an additional project in the coming week for a very important client. This frustrates the woman, who already feels that she works too many hours. Instead of discussing her feelings directly with her boss, the woman leaves a voice message for her boss the next day and deceitfully says she cannot come to work for the next week because of a family emergency. Which of the following psychological defense mechanisms is this individual demonstrating?

A. Displacement
B. Acting out
C. Malingering
D. Passive aggression (Correct Answer)
E. Blocking

Explanation: ***Passive aggression*** - This defense mechanism involves expressing negative feelings indirectly instead of openly addressing the conflict or frustrating situation. The woman's **deceitful excuse** avoids confrontation while still 'punishing' the boss by not being available. - It often stems from a fear of direct confrontation and a need to control the situation without appearing openly hostile, manifesting as **procrastination, stubbornness, or intentional inefficiency**. *Displacement* - **Displacement** occurs when a person redirects uncomfortable feelings from the source of frustration to a safer, less threatening target. - In this scenario, the woman did not redirect her frustration onto another person or object; instead, she acted on the source of the frustration indirectly. *Acting out* - **Acting out** involves expressing unconscious emotional conflicts or stressors through immediate physical actions, often impulsive or destructive. - The woman's behavior, while deceitful, is a calculated avoidance rather than an uncontrolled emotional outburst. *Malingering* - **Malingering** is the intentional production of false or grossly exaggerated physical or psychological symptoms, motivated by external incentives like avoiding work or obtaining financial compensation. - While there is an element of deceit, the primary motivation described is her frustration and desire to avoid the extra work, not necessarily an external material gain typically associated with malingering. *Blocking* - **Blocking** is a defense mechanism characterized by a temporary but sudden and complete loss of thought, often due to an emotional conflict. The individual's mind goes blank. - The woman is not experiencing a loss of thought but is actively fabricating an excuse to avoid a difficult situation.

Question 2: A researcher is conducting a study to compare fracture risk in male patients above the age of 65 who received annual DEXA screening to peers who did not receive screening. He conducts a randomized controlled trial in 900 patients, with half of participants assigned to each experimental group. The researcher ultimately finds similar rates of fractures in the two groups. He then notices that he had forgotten to include 400 patients in his analysis. Including the additional participants in his analysis would most likely affect the study's results in which of the following ways?

A. Wider confidence intervals of results
B. Increased probability of committing a type II error
C. Decreased significance level of results
D. Increased external validity of results
E. Increased probability of rejecting the null hypothesis when it is truly false (Correct Answer)

Explanation: ***Increased probability of rejecting the null hypothesis when it is truly false*** - Including more participants increases the **statistical power** of the study, making it more likely to detect a true effect if one exists. - A higher sample size provides a more precise estimate of the population parameters, leading to a greater ability to **reject a false null hypothesis**. *Wider confidence intervals of results* - A larger sample size generally leads to **narrower confidence intervals**, as it reduces the standard error of the estimate. - Narrower confidence intervals indicate **greater precision** in the estimation of the true population parameter. *Increased probability of committing a type II error* - A **Type II error** (false negative) occurs when a study fails to reject a false null hypothesis. - Increasing the sample size typically **reduces the probability of a Type II error** because it increases statistical power. *Decreased significance level of results* - The **significance level (alpha)** is a pre-determined threshold set by the researcher before the study begins, typically 0.05. - It is independent of sample size and represents the **acceptable probability of committing a Type I error** (false positive). *Increased external validity of results* - **External validity** refers to the generalizability of findings to other populations, settings, or times. - While a larger sample size can enhance the representativeness of the study population, external validity is primarily determined by the **sampling method** and the study's design context, not just sample size alone.

Question 3: A pharmaceutical company conducts a randomized clinical trial to demonstrate that their new anticoagulant drug, Aclotsaban, prevents more thrombotic events following total knee arthroplasty than the current standard of care. A significant number of patients are lost to follow-up, and many fail to complete treatment according to the study arm to which they were assigned. Despite these protocol deviations, the results for the patients who completed the course of Aclotsaban are encouraging. Which of the following analytical approaches is most appropriate for the primary analysis to establish the efficacy of Aclotsaban?

A. Intention-to-treat analysis (Correct Answer)
B. Sub-group analysis
C. Per-protocol analysis
D. As-treated analysis
E. Non-inferiority analysis

Explanation: ***Intention-to-treat analysis*** - **Intention-to-treat (ITT) analysis** is the gold standard for the **primary analysis in superiority trials** and includes all patients in the groups to which they were originally randomized, regardless of protocol deviations, loss to follow-up, or treatment discontinuation. - ITT preserves **randomization balance**, prevents bias from selective dropout (patients may drop out due to adverse effects or lack of efficacy), and provides a **conservative, realistic estimate** of treatment effect in actual clinical practice. - For **regulatory approval and establishing efficacy**, ITT is the most appropriate primary analysis method even when dropout rates are high, as it maintains the integrity of the randomized comparison. *Per-protocol analysis* - **Per-protocol analysis** includes only patients who completed the study exactly as planned without protocol deviations. - While the encouraging results in completers are noted, per-protocol analysis can **introduce significant bias** by excluding patients who dropped out due to adverse events or lack of efficacy, potentially **overestimating treatment benefit**. - Per-protocol is typically used as a **secondary/supportive analysis**, not the primary method for establishing superiority. *As-treated analysis* - **As-treated analysis** categorizes patients according to the treatment they actually received rather than their randomized assignment. - This violates the principle of randomization and can introduce **confounding bias**, as actual treatment received may be influenced by prognostic factors. *Sub-group analysis* - **Sub-group analysis** evaluates treatment effects within specific patient subsets. - This is **hypothesis-generating** rather than confirmatory and increases the risk of false-positive findings (multiple comparisons problem) unless pre-specified in the protocol. *Non-inferiority analysis* - **Non-inferiority analysis** tests whether a new treatment is not worse than control by more than a pre-specified margin. - The goal here is to demonstrate **superiority** (better than standard care), not non-inferiority, making this approach inappropriate.

Question 4: In the study, all participants who were enrolled and randomly assigned to treatment with pulmharkimab were analyzed in the pulmharkimab group regardless of medication nonadherence or refusal of allocated treatment. A medical student reading the abstract is confused about why some participants assigned to pulmharkimab who did not adhere to the regimen were still analyzed as part of the pulmharkimab group. Which of the following best reflects the purpose of such an analysis strategy?

A. To minimize type 2 errors
B. To assess treatment efficacy more accurately
C. To reduce selection bias (Correct Answer)
D. To increase internal validity of study
E. To increase sample size

Explanation: ***To reduce selection bias*** - Analyzing participants in their originally assigned groups, regardless of adherence, is known as **intention-to-treat (ITT) analysis**. - This method helps **preserve randomization** and minimizes **selection bias** that could arise if participants who did not adhere to treatment were excluded or re-assigned. - **This is the most direct and specific purpose** of ITT analysis - preventing systematic differences between groups caused by post-randomization exclusions. *To minimize type 2 errors* - While ITT analysis affects statistical power, its primary purpose is not specifically to minimize **type 2 errors** (false negatives). - ITT analysis may sometimes *increase* the likelihood of a type 2 error by diluting the treatment effect due to non-adherence. *To assess treatment efficacy more accurately* - ITT analysis assesses the **effectiveness** of *assigning* a treatment in a real-world setting, rather than the pure biological **efficacy** of the treatment itself. - Efficacy is better assessed by a **per-protocol analysis**, which only includes compliant participants. - ITT provides a more **conservative** and **pragmatic** estimate of treatment effect. *To increase internal validity of study* - While ITT analysis does contribute to **internal validity** by maintaining randomization, this is a **broader, secondary benefit** rather than the primary purpose. - Internal validity encompasses many aspects of study design; ITT specifically addresses **post-randomization bias prevention**. - The more precise answer is that ITT reduces **selection bias**, which is one specific threat to internal validity. - Many other design features also contribute to internal validity (blinding, standardized protocols, etc.), making this option less specific. *To increase sample size* - ITT analysis includes all randomized participants, so it maintains the initial **sample size** that was randomized. - However, the primary purpose is to preserve the integrity of randomization and prevent bias, not simply to increase the number of participants in the final analysis.

Question 5: An experimental drug, ES 62, is being studied. It prohibits the growth of vancomycin-resistant Staphylococcus aureus. It is highly lipid-soluble. The experimental design is dependent on a certain plasma concentration of the drug. The target plasma concentration is 100 mmol/dL. Which of the following factors is most important for calculating the appropriate loading dose?

A. Volume of distribution (Correct Answer)
B. Half-life of the drug
C. Therapeutic index
D. Clearance of the drug
E. Rate of administration

Explanation: **Volume of distribution** - The **loading dose** is primarily determined by the desired **plasma concentration** and the **volume of distribution (Vd)**, as it reflects how extensively a drug is distributed in the body. - The formula for loading dose is: Loading Dose = (Target Plasma Concentration × Vd). *Half-life of the drug* - The **half-life** is crucial for determining the **dosing interval** and the time it takes to reach **steady-state concentrations**, not the initial loading dose. - It reflects the rate at which the drug is eliminated from the body. *Therapeutic index* - The **therapeutic index** is a measure of a drug's relative safety, indicating the ratio between the **toxic dose** and the **effective dose**. - While important for drug safety, it does not directly determine the magnitude of the loading dose itself. *Clearance of the drug* - **Clearance** is the rate at which the drug is removed from the body and is a primary determinant of the **maintenance dose** required to sustain a desired plasma concentration. - It does not directly calculate the initial loading dose needed to achieve an immediate target concentration. *Rate of administration* - The **rate of administration** (e.g., infusion rate) primarily influences how quickly the drug reaches its target concentration, but not the total quantity of drug needed for the initial loading dose. - It affects the kinetics of how the loading dose achieves the target concentration, rather than defining the dose amount.

Question 6: A research group wants to assess the safety and toxicity profile of a new drug. A clinical trial is conducted with 20 volunteers to estimate the maximum tolerated dose and monitor the apparent toxicity of the drug. The study design is best described as which of the following phases of a clinical trial?

A. Phase 0
B. Phase III
C. Phase V
D. Phase II
E. Phase I (Correct Answer)

Explanation: ***Phase I*** - **Phase I clinical trials** involve a small group of healthy volunteers (typically 20-100) to primarily assess **drug safety**, determine a safe dosage range, and identify side effects. - The main goal is to establish the **maximum tolerated dose (MTD)** and evaluate the drug's pharmacokinetic and pharmacodynamic profiles. *Phase 0* - **Phase 0 trials** are exploratory studies conducted in a very small number of subjects (10-15) to gather preliminary data on a drug's **pharmacodynamics and pharmacokinetics** in humans. - They involve microdoses, not intended to have therapeutic effects, and thus cannot determine toxicity or MTD. *Phase III* - **Phase III trials** are large-scale studies involving hundreds to thousands of patients to confirm the drug's **efficacy**, monitor side effects, compare it to standard treatments, and collect information that will allow the drug to be used safely. - These trials are conducted after safety and initial efficacy have been established in earlier phases. *Phase V* - "Phase V" is not a standard, recognized phase in the traditional clinical trial classification (Phase 0, I, II, III, IV). - This term might be used in some non-standard research contexts or for post-marketing studies that go beyond Phase IV surveillance, but it is not a formal phase for initial drug development. *Phase II* - **Phase II trials** involve several hundred patients with the condition the drug is intended to treat, focusing on **drug efficacy** and further evaluating safety. - While safety is still monitored, the primary objective shifts to determining if the drug works for its intended purpose and at what dose.

Question 7: An epidemiologist is evaluating the efficacy of Noxbinle in preventing HCC deaths at the population level. A clinical trial shows that over 5 years, the mortality rate from HCC was 25% in the control group and 15% in patients treated with Noxbinle 100 mg daily. Based on this data, how many patients need to be treated with Noxbinle 100 mg to prevent, on average, one death from HCC?

A. 20
B. 73
C. 10 (Correct Answer)
D. 50
E. 100

Explanation: ***10*** - The **number needed to treat (NNT)** is calculated by first finding the **absolute risk reduction (ARR)**. - **ARR** = Risk in control group - Risk in treatment group = 25% - 15% = **10%** (or 0.10). - **NNT = 1 / ARR** = 1 / 0.10 = **10 patients**. - This means that **10 patients must be treated with Noxbinle to prevent one death from HCC** over 5 years. *20* - This would result from an ARR of 5% (1/0.05 = 20), which is not supported by the data. - May arise from miscalculating the risk difference or incorrectly halving the actual ARR. *73* - This value does not correspond to any standard calculation of NNT from the given mortality rates. - May result from confusion with other epidemiological measures or calculation error. *50* - This would correspond to an ARR of 2% (1/0.02 = 50), which significantly underestimates the actual risk reduction. - Could result from incorrectly calculating the difference as a proportion rather than absolute percentage points. *100* - This would correspond to an ARR of 1% (1/0.01 = 100), grossly underestimating the treatment benefit. - May result from confusing ARR with relative risk reduction or other calculation errors.

Question 8: You are currently employed as a clinical researcher working on clinical trials of a new drug to be used for the treatment of Parkinson's disease. Currently, you have already determined the safe clinical dose of the drug in a healthy patient. You are in the phase of drug development where the drug is studied in patients with the target disease to determine its efficacy. Which of the following phases is this new drug currently in?

A. Phase 4
B. Phase 1
C. Phase 2 (Correct Answer)
D. Phase 0
E. Phase 3

Explanation: ***Phase 2*** - **Phase 2 trials** involve studying the drug in patients with the target disease to assess its **efficacy** and further evaluate safety, typically involving a few hundred patients. - The question describes a stage after safe dosing in healthy patients (Phase 1) and before large-scale efficacy confirmation (Phase 3), focusing on efficacy in the target population. *Phase 4* - **Phase 4 trials** occur **after a drug has been approved** and marketed, monitoring long-term effects, optimal use, and rare side effects in a diverse patient population. - This phase is conducted post-market approval, whereas the question describes a drug still in development prior to approval. *Phase 1* - **Phase 1 trials** primarily focus on determining the **safety and dosage** of a new drug in a **small group of healthy volunteers** (or sometimes patients with advanced disease if the drug is highly toxic). - The question states that the safe clinical dose in a healthy patient has already been determined, indicating that Phase 1 has been completed. *Phase 0* - **Phase 0 trials** are exploratory, very early-stage studies designed to confirm that the drug reaches the target and acts as intended, typically involving a very small number of doses and participants. - These trials are conducted much earlier in the development process, preceding the determination of safe clinical doses and large-scale efficacy studies. *Phase 3* - **Phase 3 trials** are large-scale studies involving hundreds to thousands of patients to confirm **efficacy**, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug to be used safely. - While Phase 3 does assess efficacy, it follows Phase 2 and is typically conducted on a much larger scale before submitting for regulatory approval.

Question 9: A pharmaceutical company conducts a randomized clinical trial in an attempt to show that their new anticoagulant drug prevents more thrombotic events following total knee arthroplasty than the current standard of care. However, a significant number of patients are lost to follow-up or fail to complete treatment according to the study arm to which they were assigned. Several patients in the novel drug arm are also switched at a later time to a novel anticoagulant or warfarin per their primary care physician. All patients enrolled in the study are subsequently analyzed based on the initial group they were assigned to and there is a significant improvement in outcome of the new drug. What analysis most appropriately describes this trial?

A. Per protocol
B. As treated
C. Non-inferiority
D. Intention to treat (Correct Answer)
E. Modified intention to treat

Explanation: ***Intention to treat*** - **Intention-to-treat (ITT)** analysis includes all participants randomized to a treatment arm, regardless of whether they completed the intervention or switched treatments, reflecting a real-world scenario and preserving randomization benefits. - This approach minimizes bias from **loss to follow-up** or **treatment crossovers** and provides a more conservative estimate of treatment effect. *Per protocol* - **Per-protocol analysis** only includes participants who completed the study exactly as planned without any deviations. - This method is susceptible to **selection bias** because it excludes patients who may have experienced adverse events or treatment failures, potentially overestimating treatment efficacy. *As treated* - **As-treated analysis** analyzes patients based on the actual treatment received, rather than the treatment to which they were randomized. - This approach can introduce **confounding** and selection bias, as patients who switch treatments may do so for reasons related to their prognosis or treatment response. *Non-inferiority* - A **non-inferiority trial** design aims to show that a new treatment is not appreciably worse than an active control, rather than proving superiority. - This describes a **type of study design** or hypothesis, not an analysis method for handling patient data after randomization with non-adherence. *Modified intention to treat* - A **modified intention-to-treat (mITT)** analysis typically excludes a small, predefined group of patients from the ITT population, such as those who never received any study drug or were found to be ineligible after randomization. - While similar to ITT, it involves specific exclusions that are not described in this scenario, where all randomized patients were analyzed **based on initial assignment**.

Question 10: A study seeks to investigate the therapeutic efficacy of treating asymptomatic subclinical hypothyroidism in preventing symptoms of hypothyroidism. The investigators found 300 asymptomatic patients with subclinical hypothyroidism, defined as serum thyroid-stimulating hormone (TSH) of 5 to 10 μU/mL with normal serum thyroxine (T4) levels. The patients were randomized to either thyroxine 75 μg daily or placebo. Both investigators and study subjects were blinded. Baseline patient characteristics were distributed similarly in the treatment and control group (p > 0.05). Participants' serum T4 and TSH levels and subjective quality of life were evaluated at a 3-week follow-up. No difference was found between the treatment and placebo groups. Which of the following is the most likely explanation for the results of this study?

A. Observer effect
B. Berkson bias
C. Latency period (Correct Answer)
D. Confounding bias
E. Lead-time bias

Explanation: ***Latency period*** - A **latency period** refers to the time between exposure to a cause (e.g., treatment) and the manifestation of its effects (e.g., symptom improvement). The study's **3-week follow-up is too short** to observe the therapeutic benefits of thyroxine in subclinical hypothyroidism. - Levothyroxine (T4) has a **half-life of approximately 7 days**, and it typically takes **6-8 weeks or longer** for steady-state levels to be achieved and for clinical symptoms to improve. The slow onset of action for thyroid hormone replacement and the gradual nature of symptom resolution mean a longer observation period (typically 3-6 months) is needed to assess efficacy in hypothyroidism. - The null results likely reflect insufficient follow-up time rather than lack of treatment effect. *Observer effect* - The **observer effect**, or Hawthorne effect, occurs when subjects change their behavior because they know they are being observed. This study used **double-blinding** (both investigators and subjects), which effectively minimizes the observer effect. - The primary issue here is the lack of observed therapeutic effect due to timing, not a change in behavior due to observation. *Berkson bias* - **Berkson bias** is a form of selection bias that arises in case-control studies conducted in hospitals, where the probability of being admitted to the hospital can be affected by both exposure and disease. - This study is a **randomized controlled trial**, not a case-control study, and the selection of participants does not illustrate this specific bias. *Confounding bias* - **Confounding bias** occurs when an extraneous variable is associated with both the exposure and the outcome, distorting the observed relationship. The study states that **baseline patient characteristics were similarly distributed (p > 0.05)**, indicating successful randomization and minimization of confounding. - While confounding is a common concern in observational studies, the RCT design and reported baseline similarities make it unlikely to be the primary explanation for the null results compared to an insufficient follow-up period. *Lead-time bias* - **Lead-time bias** is a form of detection bias where early detection of a disease through screening appears to prolong survival, even if the treatment does not change the course of the disease. - This study is evaluating the **efficacy of treatment** in asymptomatic individuals with subclinical hypothyroidism, not the effect of screening on survival, making lead-time bias irrelevant to these results.

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free